文献库搜索 | GeneLibs

Pineda(B),Martinez-Pretel(JJ),Sanchez-Serr... Front Oncol None

...BRCA2 and TP53, which are associated with chemotherapy sensitivity. Olaparib, a PARP inhibitor, provides the greatest cl...

Liu(S),Hu(H) Discov Oncol 2026-04-20

...BRCA2, and others. CONCLUSION: This report describes a breast tumor exhibiting concurrent features of AcCC and matrix-pr...

Guan(J),Hu(J),Lin(S),Chen(C),Luo(Y),Zhou(W... BMC Res Notes 2026-04-20

...BRCA2 were each detected in 3 cases; (3) In breast cancer patients carrying BRCA and BRCA1 mutations, the negative rates...

Liu(H),Zhang(M),Xu(Z),Yang(Z),Pan(Y),Bai(Y... Nucleic Acids Res 2026-04-13

...BRCA2 interaction and HR efficiency. Clinically, PFKP exhibits significant nuclear accumulation in diabetes-associated m...

Tsubouchi(H),Iwasaki(H) Trends Genet 2026-07-00

...BRCA2 was restricted to higher eukaryotes. However, the identification of BRCA2 homologs across diverse fungal phyla rev...

Matkowski(R),Abrahamowska(M),Michalowska(D... BMC Cancer 2026-04-21

...BRCA2) were identified in 30 patients (2.94%; 95% CI: 2.07%–4.16%, Wilson). The most frequent variant was BRCA1 c.5266du...

Avila-Rodriguez(V),Ruiz-Patiño(A),Bonilla-... Case Rep Oncol Med None

...BRCA2, MLH1, MSH2, MSH6, PMS2, APC, TP53, PTEN, and STK11, conferring a higher risk of multiple primary malignancies. We...

Schuster(CR),Aslami(ZV),Taccheri(C),Azizi(... Breast Cancer Res Treat 2026-04-22

...BRCA2 mutation (2.3%, n = 1). Imaging revealed irregular findings in 17.1% (n = 7), with malignancy confirmed in 2 patie...

Webber(JW),Wollborn(L),Mishra(S),Alimena(S... Sci Rep 2026-03-24

...BRCA2. However, most women with HBOC are undiagnosed, and some patients meeting clinical criteria for HBOC will have no ...

Li(C),Madan(RA),Lee(MJ),Lee(S),Sato(N),Ras... J Immunother Cancer 2026-03-25

...BRCA2 variants experienced longer rPFS (13.2 months; 95% CI 7.7 to 20.2 months) than patients without BRCA2 variants (4....